PROK ProKidney
- 2.400
- +0.020+0.84%
ProKidney News
ProKidney Initiated at Buy by Guggenheim
Guggenheim Initiates Coverage On ProKidney With Buy Rating, Announces Price Target of $6
Guggenheim Initiates ProKidney(PROK.US) With Buy Rating, Announces Target Price $6
Buy Rating on ProKidney: Promising Prospects in Chronic Kidney Disease Treatment
ProKidney Drops Phase III CKD Study to Focus on US Market and Save up to $175m
BofA Securities Maintains ProKidney(PROK.US) With Hold Rating, Maintains Target Price $3
ProKidney Is Maintained at Neutral by B of A Securities
ProKidney Analyst Ratings
BofA Securities Maintains ProKidney(PROK.US) With Hold Rating, Cuts Target Price to $3
Morgan Stanley Maintains ProKidney(PROK.US) With Hold Rating, Maintains Target Price $3
Maintaining Hold on ProKidney Amid Strategic Shifts and Regulatory Uncertainties
ProKidney's Hold Rating Maintained Amid Financing and Clinical Uncertainties
BTIG Maintains ProKidney(PROK.US) With Buy Rating, Maintains Target Price $5
ProKidney: Investor Update and Phase 3 Program Progress
ProKidney Decides To Prioritize PROACT 1; Plans To Discontinue PROACT 2, Which Was Focused On Enrollment Outside US; Now Expects Current Cash To Support Operating Plans Into Q1 2027
Express News | ProKidney Corp - Believes Phase 3 Regen-016 (Proact 2) Trial Is Not Required for Initial U.S. Registration
Express News | ProKidney Corp - Focused Company Resources on Proact 1 to Expedite Enrollment and Accelerate Estimated Topline Data Readout to Q3 2027
Express News | ProKidney Corp - Discontinued Ex-U.S.-Based Proact 2 Trial
Express News | ProKidney Announces Strategic Updates to Its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S.
ProKidney Announces Strategic Updates to Its Phase 3 Program to Accelerate Rilparencel's Registrational Path to Potential Approval in the U.S.
Analysis
Price Target
No Data
No Data